Ignite Creation Date:
2024-05-06 @ 8:28 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06398366
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-05-07
First Post:
2023-12-14
Brief Title:
Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence
Sponsor:
The Cooper Health System
Organization:
The Cooper Health System
Study Overview
Official Title:
Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence CASPR A Multi-center Observational Cohort Study
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CASPR
Brief Summary:
This is a multi-center retrospective analysis of consecutive adult patients with cryptogenic stroke patients following a comprehensive workup for the underlying stroke etiology Patients will be eligible for inclusion if the index stroke event occurred between 112016 and 06302022
Detailed Description:
This is an exploratory observational cohort study of existing registry-based clinical laboratory and radiographic data There are multiple pre-specified hypotheses that will be tested using this data set which include the entire cohort as well as planned subgroup analyses The analyses center around patients with cryptogenic stroke no clear stroke mechanism but who are characterized by potential embolic sources These include but are not limited to left atrial enlargement or dysfunction left ventricular dysfunction heart failure with reduced ejection fraction HFrEF patent foramen ovale PFO paroxysmal atrial fibrillation pAF lambls excrescence valvular lesions carotid web and nonstenotic cervical arterial plaque A brief summary of several planned hypothesis is itemized below
1 To evaluate treatment practices in patients with potential embolic sources
2 To estimate the risk of recurrent stroke major bleeding andor death following an incident stroke event across various potential embolic sources
3 To compare rates of recurrent stroke major bleeding andor death across various potential embolic sources when stratified by antithrombotic treatment type
4 To evaluate type frequency and findings of long-term outpatient cardiac event monitoring for paroxysmal atrial fibrillation And furthermore to determine antithrombotic treatment changes following abnormalities detected with such monitoring
5 To develop and validate a risk prediction model for later atrial fibrillation in cryptogenic stroke by integrating a machine-learning algorithm or convolutional neural network analysis of 12-lead electrocardiographic data with clinical laboratory and radiographic parameters
6 To develop and validate a risk prediction model for later atrial fibrillation atrial fibrillation burden and recurrent stroke andor death using a machine-learning andor convolutional neural network andor validated electrophysiologic biomarkers eg p-wave morphology abstracted from outpatient telemetry when added to clinical and radiological patient profiles
7 To compare the sensitivity of various outpatient cardiac telemetry devices for identifying atrial fibrillation
8 To evaluate real-world treatment practices of patent foramen ovale closure antithrombotic therapy in patent foramen ovale and risk of stroke recurrence
9 To evaluate real-world secondary stroke prevention strategies in patients with heart failure with and without left ventricular dysfunction
1 To evaluate treatment practices in patients with potential embolic sources
2 To estimate the risk of recurrent stroke major bleeding andor death following an incident stroke event across various potential embolic sources
3 To compare rates of recurrent stroke major bleeding andor death across various potential embolic sources when stratified by antithrombotic treatment type
4 To evaluate type frequency and findings of long-term outpatient cardiac event monitoring for paroxysmal atrial fibrillation And furthermore to determine antithrombotic treatment changes following abnormalities detected with such monitoring
5 To develop and validate a risk prediction model for later atrial fibrillation in cryptogenic stroke by integrating a machine-learning algorithm or convolutional neural network analysis of 12-lead electrocardiographic data with clinical laboratory and radiographic parameters
6 To develop and validate a risk prediction model for later atrial fibrillation atrial fibrillation burden and recurrent stroke andor death using a machine-learning andor convolutional neural network andor validated electrophysiologic biomarkers eg p-wave morphology abstracted from outpatient telemetry when added to clinical and radiological patient profiles
7 To compare the sensitivity of various outpatient cardiac telemetry devices for identifying atrial fibrillation
8 To evaluate real-world treatment practices of patent foramen ovale closure antithrombotic therapy in patent foramen ovale and risk of stroke recurrence
9 To evaluate real-world secondary stroke prevention strategies in patients with heart failure with and without left ventricular dysfunction
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None